17β-Hydroxyestr-4-en-3-on-17-decanoat
DECADURABOLIN · Anabolicum · Nandrolone Deconate · Nandrolone Decanoate (DECA) · 19-NORTESTOSTERONE 17-DECANOATE · 17-beta-hydroxy-estr-4-en-3-ondecanoate · retabolil · Nand Deca
Identifikatoren & physikalische Daten
| CAS No. | 360-70-3 |
|---|---|
| Summenformel | C28H44O3 |
| Durchschnittliche Molmasse | 428,6 g/mol |
| Monoisotopische Masse | 428,32904527 g/mol |
| SMILES | CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C |
| InChIKey | JKWKMORAXJQQSR-MOPIKTETSA-N |
| PubChem CID | 9677 |
| ChEMBL | CHEMBL1200946 |
| ChEBI | CHEBI:7467 |
| EC No. | 206-639-3 |
| DTXSID | DTXSID7023352 |
| Lokaler Name | 17β-Hydroxyestr-4-en-3-on-17-decanoat |
Chemische & physikalische Eigenschaften
| XLogP | 7,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 43,4 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 10 |
| Schwere Atome | 31 |
| Formalladung | 0 |
| Komplexität | 680 |
| Arzneimittel | Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive CompoundsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 2.62 |
| Human Drugs | FDA approved drugs -> Active ingredientPharmaceuticals |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Schmelzpunkt | 32-35118 °C33-37°C |
| Physical Description | Solid |
| Siedepunkt | 483.46°C (rough estimate) |
| Dichte | 1.0406 (rough estimate) |
| Brechungsindex | 1.4700 (estimate) |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.8 mg/mL664ug/L(37 ºC) |
| Aggregatzustand | powder |
| Farbe | white to light yellow |
| InChIKey | JKWKMORAXJQQSR-MOPIKTETSA-N |
| SMILES | [C@@]12([H])CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |&1:0,4,17,21,23,33,r| |
| CAS Datenbank | 360-70-3 |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (19.5%): Toxic if swallowed [Danger Acute toxicity, oral]P203, P260, P261, P263, P264, P270, P271, P280, P301+P316, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 87 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Nandrolone decanoate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| Weitere Sicherheitsinformationen | IMAP assessments - Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17.beta.)-: Human health tier I assessment |
| Hazard Classes and Categories | Acute Tox. 4 (19.5%) |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)nandrolone decanoateDILI PositiveIntramuscularDOI:10.1016/j.drudis.2019.09.022 |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 2937290000 |
| RTECS-Nr. | KG7967000 |
| R-Sätze (R) | 40 |
| Toxizität | LD50 intraperitoneal in mouse: > 566mg/kg |
| Gefahrensymbole | Xn |
| Sicherheitshinweise (S) | 22-36 |
Anwendungen & Verwendung
Beschreibung
Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. The process for creating esters of [nandrolone] was patented in Spain in 1959 and in 1960, it was described as having a long duration of action and strong anabolic effect compared to nandrolone and other esters. Nandrolone decanoate was granted FDA approval on 5 October 1962.
Verwenden
Nandrolone Decanoate is an anabolic steroid. Nandrolone decanoate is used in the treatment of osteoporosis in postmenopausal women. Nandrolone Decanoate is also used for some aplastic anemias. Control led Substance.